Funding for two research projects at the University of California, San Diego School of Medicine are among the 76 grants announced by the Bill & Melinda Gates Foundation in the third funding round of Grand Challenges Explorations, an initiative to help scientists around the world explore bold and largely unproven ways to improve health in developing countries.
Medical clinics the world over could benefit from new software created at NIST, where a team of scientists has found a way to improve the efficiency of a pneumonia vaccine testing method developed at the University of Alabama at Birmingham.
Food and water around the world could soon become safer for human consumption thanks to a new cattle vaccine created by University of Saskatchewan graduate student David Asper.
A new cervical cancer vaccine approved Oct. 16 by the Food and Drug Administration was developed as a result of research at Loyola University Chicago Stritch School of Medicine.
A University of Illinois at Chicago study finds girls and young women do not believe the human papillomavirus vaccine protects them against other sexually transmitted infections, nor do they believe they should stop cervical cancer screening.
An apparent allergic reaction after an immunization should be investigated rather than avoiding future immunizations, which could leave patients at greater risk of disease, according to new medical guidelines.
C.S. Mott Children’s Hospital National Poll on Children’s Health finds nearly 90% of public supports required H1N1 vaccination for health care workers in case of outbreak, while only 38% of health care workers intend to get vaccinated.
Unfortunately, kids will probably be dismayed to learn that they will need an extra shot this year since recommendations call for children to receive both a seasonal flu vaccine and the H1N1 vaccine. Here are some tips to help kids survive the needle sticks.
A Q&A about the flu vaccine with Dr. David P. Calfee, Infection Control Officer, The Mount Sinai Medical Center in New York.
UNC expert available to discuss latest development in search for AIDS vaccine.
Immune therapies have been explored as a way to treat cancer after it develops. But a new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells.
A person, usually a child, dies of rabies every 20 minutes. However, only one inoculation may be all it takes for rabies vaccination, according to new research published in the Journal of Infectious Diseases by researchers at the Jefferson Vaccine Center.
University of Michigan scientists have moved closer to the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans. Half of all women and 14 percent of men experience urinary tract infections, some repeatedly.
A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.
Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.
Findings reveal an achilles heel on the virus for AIDS vaccine researchers to exploit.
The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein—a cancer vaccine—that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.
An analysis of the adverse events reported following distribution of quadrivalent human papillomavirus recombinant vaccine since 2006 indicates that adverse event rates were consistent with pre-licensing data and expected background rates of other vaccines, with the exception of a higher proportion of reports of fainting and blood clots, according to a study in the August 19 issue of JAMA.
1) Approximately 50 percent do not recommend the vaccine; 2) Those who hear scientific information more likely to recommend; 3) Study confined to Texas, but representative of national mood.
Researchers at the Johns Hopkins Malaria Research Institute have for the first time produced a malarial protein (Pfs48/45) in the proper conformation and quantity to generate a significant immune response in mice and non-human primates for use in a potential transmission-blocking vaccine. Antibodies induced by Pfs48/45 protein vaccine effectively blocked the sexual development of the malaria-causing parasite, Plasmodium, as it grows within the mosquito.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right